ARTICLE | Finance
Coming out party
BridgeBio lifts the veil on its ATTR-focused Eidos subsidiary
April 29, 2017 12:21 AM UTC
With the announcement of a $27 million commitment to its Eidos Therapeutics Inc. subsidiary, two-year-old BridgeBio Pharma is beginning to lift the veil on its portfolio of rare genetic disease plays.
Eidos, which is developing transthyretin (TTR)-mediated amyloidosis (ATTR) candidate AG10, is one of nine BridgeBio subsidiaries focused on single assets or diseases...
BCIQ Company Profiles
BCIQ Target Profiles